Details:

Corporate Authors:
National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases.
Description:
CDC is conducting a nationwide COVID-19 seroprevalence survey in 25 U.S. metropolitan areas to understand the percentage of people in the United States who may have been infected with SARS-CoV-2, the virus that causes COVID-19.

This is the largest nationwide COVID-19 seroprevalence survey to date, and it will be conducted in collaboration with the National Institutes of Health, the Food and Drug Administration (FDA), Vitalant Research Institute (VRI), and large blood collection organizations, including Vitalant, American Red Cross, Bloodworks Northwest, New York Blood Center, OneBlood, The Blood Center, Versity, Blood Bank of Hawaii, Carter Blood Care, and Banco de Sangre de Servicios Mutuos.

This seroprevalence survey will expand an ongoing National Institute of Allergy and Infectious Diseases and National Heart, Lung and Blood Institute (NHLBI) funded project with VRI that involves the NHLBI REDS (Recipient Epidemiology and Donor Evaluation Study)external icon program. The SARS-CoV-2 REDS project plans to test existing blood donation samples from Boston, MA; Los Angeles, CA; Minneapolis, MN; New York City, NY; San Francisco, CA; and Seattle, WA for SARS-CoV-2 antibodies each month for 6 months from March through August 2020.

As part of this collaboration, CDC will provide technical assistance and financial support to VRI and collaborating institutions that will allow the survey to be expanded to 19 additional metropolitan areas including Atlanta, GA; Baltimore, MD/Washington, D.C.; Chicago, IL; Dallas/Ft Worth, TX; Denver, CO; Detroit, MI; Fargo, ND/Sioux Falls/Rapid City, SD; Honolulu, HI; Las Vegas, NV; Miami, FL; Milwaukee, WI; New Orleans, LA; Phoenix, AZ; Pittsburg, PA; Salt Lake City, UT; San Juan, PR; St. Louis, MO; Tampa/St. Petersburg, FL; and Tulsa, OK.

VRI and collaborating organizations will collect and test about 1,000 anonymous blood donation samples from each of the 25 total metropolitan areas. They will test samples each month for 12 months, and again at 18 months. About 325,000 samples will be tested overall. Because this survey will collect samples from major metropolitan areas across the country at different time points, its findings will help scientists estimate the percentage of previous SARS-CoV-2 infections out of the total U.S. population. It also will track how the percentage of previous infections is changing over time.


Content Notes:
About this survey -- Information on blood donation samples tested -- Safety of US blood supply -- Interpreting Serology Results from This Survey.
Subjects:
[+]
Betacoronavirus Blood Donors Clinical Laboratory Techniques Coronavirus Infections/diagnosis COVID-19 Neutralization Tests Pandemics Pneumonia, Viral Prevalence Real-Time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction Seroepidemiologic Studies
Document Type:
Webpage
Collection(s):
Stephen B. Thacker CDC Library collection
Main Document Checksum:
[+]
urn:sha256:fe29c3573334a7a327a3c680198f7939f95f807bc78f88a96a4724280ccb4e5f
Download URL:
https://stacks.cdc.gov/view/cdc/90252/cdc_90252_DS1.pdf
File Type:

Supporting Files

• blood-bank-serosurvey.html

  htm

More +